Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Synthesis and characterization of a high-affinity αvβ6-specific ligand for in vitro and in vivo applications

Shunzi Li, Michael J. McGuire, Mai Lin, Ying-Horng Liu, Tsukasa Oyama, Xiankai Sun and Kathlynn C. Brown
Shunzi Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. McGuire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mai Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying-Horng Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsukasa Oyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiankai Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathlynn C. Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-1098 Published May 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Synthetic scheme for the convergent synthesis of tetrameric peptides. H2009.1 peptide sequence: RGDLATLRQLAQEDGVVGVR, RGDLATLRQL, or RGDLATL.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Inhibition of bacteriophage uptake by different peptide scaffolds synthesized by the convergent strategy. The normalized phage uptake is defined as the ratio of output phage to input phage in the presence of peptide normalized to the output/input ratio of phage with no peptide added (1, 18). The number of input phage particles was held constant. Error bars, SE measurement of a minimum of three replicates. A, comparison of the inhibition of bacteriophage uptake by the H2009.1 20-mer peptides prepared by either convergent or linear synthesis. Synthesis of the peptide by linear synthesis and its ability to block phage uptake has been previously reported (16). B, the truncated 10-mer peptide blocks uptake of the H2009.1 phage clone as efficiently as the full-length 20-mer H2009.1 peptide. Single amino acid deletions from the carboxy terminus reveal that the minimal binding domain is a seven-amino-acid peptide. C, comparison of effect of peptide length on binding when placed on the trilysine core. D, evaluation of the effect of valency on peptide affinity.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The tetrameric 10-mer H2009.1 peptide mediates cellular uptake. A, H2009 cells were incubated for 10 min at 37°C with 1 μmol/L H2009.1 10-mer tetramer-Alexa Fluor 488 conjugate. Images were captured on a Leica TCS SP5 confocal microscope at 400× magnification with 7× optical zoom. Images are presented as an overlay series of 18 frames from the Z-stack acquisition (left). A single z-series slice from the image obtained in frame to the left is shown (middle). The H2009.1 10-mer tetrameric peptide mediates cellular uptake of Qdots in H2009 cells (right). The peptide was conjugated to the Qdot through a streptavidin-biotin interaction. Cells were incubated with 20 nmol/L of the SAQdot605-conjugated tetrameric H2009.1 peptide. In all panels, similar data were collected from distinct areas of the slide. B, H2009.1 cells were treated with H2009.1-Qdot conjugate (right) or H1299.2-Qdot conjugate (left). After incubation, the cells were fixed, permeabilized, and stained for β6 (green). Within the 10-min incubation time, the H2009.1-Qdot conjugate and the β6 integrin are internalized. Colocalization of the H2009.1-Qdot conjugate and β6 is indicated by the yellow color and pointed out by the arrows for several cells. H2009 cells do not mediate uptake of the H1299.2-Qdot conjugate (left). Additionally, the β6 integrin remains on the cell surface. C, uptake of peptide-conjugated Qdots is independent of cell cycle progression. Cells were cultured overnight in eight-well chamber slides before incubation with 10 nmol/L Qdot-H2009.1 peptide conjugate for 10 min at 37°C. Wells were washed and fixed in PBS-buffered formalin as detailed in Experimental Procedures. Cellular DNA was stained with 4′,6-diamidino-2-phenylindole (top left) and the cell membrane was stained with wheat germ agglutinin-Alexa Fluor 488 (top right). Bottom left, Qdot uptake; bottom right, an overlay of the three images. Arrows, cells captured during mitosis: a, prophase; b, metaphase; c, early anaphase; and d, late telophase/cytokinesis.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    The H2009.1 10-mer tetrameric peptide can be used in diagnostic formats. A, formalin-fixed, paraffin-embedded tumor sections were stained with H&E (top left) or H2009.1 10-mer peptide-labeled Qdots (top right and bottom left) or Qdots with no peptide (bottom right). Bottom left (400× magnification), peptide-labeled Qdot staining (red) is associated with intact tumor cells as indicated by the staining of nuclei (blue), whereas unlabeled Qdots exhibit minimal cellular staining. At 100× magnification (top right), the labeled Qdot staining appears uniform throughout the tumor. Similar results were observed with independently prepared tumor specimens. B, the H2009.1 10-mer tetrameric peptide can be used as a flow cytometry reagent to bind to αvβ6-positive cells. Cells (αvβ6-positive H2009 cells and αvβ6-negative H460 cells; ref. 2) were incubated for 1 h with H2009.1 10-mer peptide-Alexa Fluor 488 conjugate or scrambled peptide-dye conjugate, washed, and evaluated for peptide-dye uptake by flow cytometry. Cells were gated by cell volume and side scatter to remove cell fragments and debris from analysis. A total of 10,000 events were evaluated for fluorescence in channel 1 (excitation at 488 nm, emission at 500–550 nm). The data shown were obtained at 10 nmol/L peptide-dye conjugate concentration.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Structure of the DOTA-labeled tetrameric peptide.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Serum stability of H2009.1 peptides

    1 h4 h
    % Intact% Intact
    H2009.1 10-mer-PEG11-DOTA6046
    H2009.1 10-mer-tetramer (convergent)7669
    H2009.1 10-mer-tetramer (linear)7363

Additional Files

  • Figures
  • Tables
  • Supplementary Materials, Li et al

    Files in this Data Supplement:

    • Supplementary Data
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (5)
May 2009
Volume 8, Issue 5
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis and characterization of a high-affinity αvβ6-specific ligand for in vitro and in vivo applications
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Synthesis and characterization of a high-affinity αvβ6-specific ligand for in vitro and in vivo applications
Shunzi Li, Michael J. McGuire, Mai Lin, Ying-Horng Liu, Tsukasa Oyama, Xiankai Sun and Kathlynn C. Brown
Mol Cancer Ther May 1 2009 (8) (5) 1239-1249; DOI: 10.1158/1535-7163.MCT-08-1098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis and characterization of a high-affinity αvβ6-specific ligand for in vitro and in vivo applications
Shunzi Li, Michael J. McGuire, Mai Lin, Ying-Horng Liu, Tsukasa Oyama, Xiankai Sun and Kathlynn C. Brown
Mol Cancer Ther May 1 2009 (8) (5) 1239-1249; DOI: 10.1158/1535-7163.MCT-08-1098
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Experimental Procedures
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PX-478 Radiosensitization in Pancreatic Cancer
  • Metronomic Gemcitabine Inhibits Pancreatic Cancer
  • p53-Deficient Cells Are More Sensitive to Plk1 Inhibitor
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement